4F-MPH
4-fluoromethylphenidate
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
4F-MPH (4-fluoromethylphenidate) is an emerging synthetic stimulant of the substituted phenidate class. It is a fluorinated structural analog of methylphenidate, approximately twice as potent per milligram.[1] 4F-MPH is a dopamine and norepinephrine reuptake inhibitor, producing its effects by blocking the clearance of these neurotransmitters from the synapse without triggering their release.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylphenidate, ethylphenidate, isopropylphenidate +1 moremethylphenidate, ethylphenidate, isopropylphenidate, other phenidate analogs show less
4F-MPH appeared on online research chemical markets in 2015, emerging as a replacement after the United Kingdom banned ethylphenidate.[1] The EMCDDA issued an Early Warning System notification in November 2015,[3] and the first published pharmacological characterization confirmed its potency and mechanism. It circulates in most jurisdictions as a grey-market "research chemical," marketed primarily as a cognitive enhancer and productivity aid.[4]
Subjective effects include focus enhancement, wakefulness, thought acceleration, appetite suppression, and emotional suppression. The experience is characteristically mechanical — a dry, task-oriented stimulation with minimal warmth or euphoria, closer to an amplified work state than a recreational high. Compulsive redosing, anxiety at higher doses, and a dysphoric comedown disproportionate to the modest high are common unsought effects.
Dependence liability is high based on its DAT selectivity profile,[5] and no lethal dose has been established in any species. Cardiovascular toxicity — elevated heart rate and blood pressure — is the primary acute danger, amplified by 4F-MPH's greater potency relative to methylphenidate;[6] one confirmed mono-intoxication required emergency sedation,[7] and a single US fatality involved severe polydrug co-ingestion.[8] No clinical trials, pharmacokinetic studies, or controlled safety assessments have been conducted — the current understanding rests on two in vitro papers, two case reports, and community self-reports.
History[edit]
Discovery
Methylphenidate, the parent scaffold, was first synthesized in 1944 and introduced clinically a decade later. 4-Fluoromethylphenidate emerged not from pharmaceutical research but from grey-market synthesis, appearing on online research chemical vendors in 2015 after the United Kingdom's temporary class drug order banned ethylphenidate.[1] The first published pharmacological characterization, by McLaughlin and colleagues, established its transporter binding profile and identified significant diastereomeric variation between commercial batches.[1]
Regulatory response and detection
The EMCDDA issued its first Early Warning System notification for 4F-MPH in November 2015.[3] The compound was first detected in North American drug paraphernalia in 2016 and first identified in a US biological specimen in 2018, in a fatal polydrug case — the first American death with 4F-MPH listed on the death certificate.[8] Several jurisdictions have since enacted specific controls, including the United Kingdom (Class B, 2017) and Canada (controlled, 2017).[9]
Market positioning
4F-MPH has been marketed online as a cognitive enhancer and productivity aid — positioned as a "functional" stimulant distinct from recreational cathinone- or amphetamine-type novel psychoactive substances.[4] Qualitative research has documented its use for self-medication of ADHD symptoms among individuals without access to prescribed stimulants,[4][10] though this functional framing is pharmacologically superficial: 4F-MPH's high DAT selectivity predicts substantial abuse liability regardless of user intent.
Chemistry[edit]
Structural class
4F-MPH belongs to the substituted phenidate class — compounds built on the methylphenidate scaffold of a piperidine ring connected to a phenyl-substituted acetic acid ester. It differs from methylphenidate solely by a fluorine atom at the para position of the phenyl ring, a common medicinal chemistry modification that typically increases lipophilicity and metabolic stability while modestly enhancing target binding. Other members of this series include ethylphenidate, isopropylphenidate (IPPD), and 4-methylmethylphenidate (4-MeTMP).
Molecular properties
| Molecular formula | C₁₄H₁₈FNO₂ |
| Molecular weight (free base) | 251.30 g/mol |
| Molecular weight (HCl salt) | ~287.8 g/mol |
Stereochemistry
Two chirality centers produce two diastereomer pairs: (±)-threo and (±)-erythro. The distinction is pharmacologically decisive — the threo form is responsible for essentially all stimulant activity, while the erythro form is approximately 140-fold weaker at the DAT.[1]
Commercial products vary in diastereomeric composition: one vendor's product contained exclusively threo-4F-MPH while another from the same vendor was a threo/erythro mixture.[1] Users accustomed to one batch may experience unexpectedly stronger effects when switching to a purer threo preparation — a direct safety concern in a market with no quality controls.
Thermal instability
Phenidate analogs including 4F-MPH decompose at the temperatures encountered in analytical gas chromatography and, by extension, in smoking or vaping equipment.[11] Heating the compound produces degradation products rather than intact parent substance, rendering thermal routes of administration both unreliable and potentially harmful.
Physical characteristics
4F-MPH circulates as a white crystalline powder. Published physical property values — including melting point (~147–148 °C for the HCl salt) and boiling point (329.4 °C predicted) — are derived from commercial sources and computational models; none have been experimentally verified in peer-reviewed literature.[12]
Pharmacology[edit]
Mechanism of action
4F-MPH blocks the DAT (DAT) and NET (NET), preventing these neurotransmitters from being cleared from the synapse and thereby amplifying their signaling.[1][2] It does not trigger the release of monoamines — a distinction that separates all phenidate-class compounds from amphetamine-type stimulants, which actively push neurotransmitters out of nerve terminals.[13]
The pharmacologically active form — (±)-threo-4F-MPH — is approximately twice as potent as methylphenidate at the dopamine transporter and nearly three times as potent at the norepinephrine transporter.[1] Serotonin transporter affinity is negligible, making 4F-MPH a highly catecholamine-selective compound. This selectivity profile — strong dopamine blockade with minimal serotonin activity — is associated with elevated abuse potential among reuptake inhibitors.[5]
Luethi and colleagues confirmed that methylphenidate-based novel psychoactive substances including 4F-MPH function exclusively as uptake blockers, not releasers, but emphasized that their predominant dopamine transporter activity nonetheless indicates high reinforcement potential.[2]
Pharmacokinetics
No human pharmacokinetic studies have been published for 4F-MPH. Onset, duration, plasma half-life, bioavailability, and elimination parameters remain entirely uncharacterized in controlled settings.
Animal studies have identified 13 metabolites in rat urine, with the primary pathway being hydrolysis to a fluorinated ritalinic acid structural analog — paralleling methylphenidate's well-characterized metabolism.[14] Human liver preparations confirmed the same hydrolytic pattern in vitro.[14] These carboxy metabolites serve as additional analytical targets for forensic screening alongside the parent compound.
Duration estimates derive entirely from community reports: oral administration produces effects lasting 4–8 hours with onset in 30–60 minutes; insufflation yields a shorter 3–6 hour duration with onset in 10–30 minutes.[15] Whether the structural fluorination meaningfully alters the metabolic profile relative to methylphenidate remains an open question.
Neuroscience[edit]
Where it acts
No neuroimaging or electrophysiological studies have been conducted with 4F-MPH; all neural mechanism inferences are extrapolated from the methylphenidate class. As a potent DAT/NET inhibitor, 4F-MPH amplifies dopamine signaling in the mesolimbic mesolimbic pathway — the circuit linking the ventral tegmental area to the nucleus accumbens that underlies motivation and reinforcement. Simultaneously, dopamine and norepinephrine enhancement in the prefrontal cortex supports the focus enhancement and thought organization reported at moderate doses, while norepinephrine potentiation from the locus coeruleus drives wakefulness, arousal, and peripheral sympathomimetic effects.
Why it matters
The inverted-U model of catecholamine function explains 4F-MPH's narrow window between cognitive enhancement and anxious overstimulation: low-to-moderate doses enhance prefrontal function, while higher doses impair it, producing anxiety and thought acceleration. Separately, incentive salience theory — the "wanting versus liking" distinction — accounts for why users report compulsive redosing despite modest euphoria: dopamine potentiation amplifies the motivational drive to redose without proportionally increasing pleasure.citation needed
Does 4F-MPH produce proportionally greater striatal dopamine transporter occupancy than methylphenidate at lower doses, as its in vitro potency predicts? What is the balance of behavioral sensitization versus tolerance with repeated exposure — the answer determines whether long-term use trends toward escalation or diminishing returns.
Subjective Effects[edit]
4F-MPH produces a characteristically "functional" stimulant experience — task-oriented cognitive enhancement and physical activation with minimal warmth or euphoria. The emotional tone tends toward flattening rather than elevation; users describe reduced emotional reactivity during the active phase, followed by a dysphoric offset disproportionate to the modest subjective high. At lower doses, the profile suits productivity-oriented use; at higher doses, the experience tips into anxious overstimulation, with compulsive redosing becoming a prominent behavioral feature — particularly via insufflation, where rapid onset sharpens reinforcement.[4]
Relative to methylphenidate, 4F-MPH is described as qualitatively similar but more potent per milligram, with a narrower margin between useful enhancement and uncomfortable overstimulation. Compared to amphetamine-type stimulants, it is perceived as less euphoriant and more "mechanical" in character — consistent with its reuptake-inhibitor-only mechanism and absence of monoamine release.[2]
Effect Grid
Clear stimulant effects are present — sustained focus enhancement, wakefulness, thought acceleration, and pronounced appetite suppression. This is the dose range most commonly reported for cognitive enhancement use. Mild euphoria is possible, particularly on initial exposures, though 4F-MPH is generally described as less euphoriant than amphetamine-type stimulants.
Pupil dilation becomes apparent. Heart rate is noticeably elevated. Mild vasoconstriction may produce cool extremities. Emotional suppression is clearly present — reduced emotional range and affective flattening are characteristic of this tier. Bruxism and mild excessive sweating may begin.
Aftereffects are disproportionately long relative to the active phase. Insomnia is likely if taken after midday. Post-use irritability, low mood, and cognitive fatigue are common during offset. Compulsive redosing urge begins to emerge, particularly via insufflated administration.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Pupil dilation · Insomnia · Dry mouth · Heart rate perception changes · Physical fatigue · Dehydration sensation · Excessive sweating · Spontaneous body sensations · Muscle tension · Restlessness · Sexual arousal enhancement · Bodily lightness · Headache · Respiratory stimulation · Temperature dysregulation · Motor control enhancement · Nausea · Bruxism · Dizziness · Constipation · Nasal congestion · Tingling / electric sensations · Trembling
Heart rate perception changes · Physical fatigue · Dehydration sensation · Excessive sweating · Spontaneous body sensations · Muscle tension · Restlessness · Sexual arousal enhancement · Bodily lightness · Headache · Respiratory stimulation · Motor control enhancement · Nausea · Bruxism · Dizziness · Constipation · Nasal congestion · Tingling / electric sensations · Trembling
Analysis enhancement · Motivation enhancement · Cognitive euphoria · Immersion enhancement · Information processing enhancement · Suggestibility suppression · Motivation suppression · Aesthetic enhancement · Thought connectivity · Memory enhancement · Thought deceleration · Cognitive impairment · Multiple thought streams · Thought loops · Thought disorganization
Information processing enhancement · Suggestibility suppression · Motivation suppression · Aesthetic enhancement · Thought connectivity · Memory enhancement · Thought deceleration · Cognitive impairment · Multiple thought streams · Thought loops · Thought disorganization
Irritability · Anhedonia · Dysphoria · Emotional lability · Empathy suppression
Empathy suppression
Communication enhancement · Self-control enhancement · Sociability enhancement · Automaticity · Sociability suppression
Sociability suppression
Timeline
Gradual build of alertness and mild stimulation. Effects may be subtle initially — a faint sharpening of attention that could be mistaken for placebo.
Full cognitive enhancement with sustained focus, thought acceleration, and appetite suppression. Emotional flattening and cardiovascular effects (elevated heart rate, vasoconstriction) are present. Compulsive redosing urge may emerge.
Stimulation fades progressively. Dysphoric rebound begins — irritability, low mood, and cognitive fatigue replace the productive clarity of the peak.
Residual wakefulness and appetite suppression persist well beyond active effects. Mood may be low. Insomnia is common even when other effects have resolved.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 5 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- methylphenidate · ethylphenidate · isopropylphenidate
Toxicity
Acute toxicity
No lethal dose has been established for 4F-MPH in any species, and no dose-finding toxicological studies exist.safety citation needed The compound can produce toxicity requiring emergency intervention on its own: a 26-year-old woman presented after one week of insufflation with agitation, altered mental status, and cardiovascular abnormalities, requiring intravenous sedation and antipsychotic medication.[7]
A single US fatality listed 4F-MPH on the death certificate, but seven additional substances were co-detected — including methamphetamine, amphetamine, and a synthetic opioid — making 4F-MPH's independent contribution to death indeterminate.[8]
Cardiovascular toxicity
Elevated heart rate, increased blood pressure, and irregular heart rhythm represent the primary acute dangers, extrapolated from the methylphenidate class.[6] Rare but documented outcomes for this class include heart attack and sudden cardiac death. Given 4F-MPH's 2–3-fold greater potency at dopamine and norepinephrine transporters,[1] cardiovascular effects may be more pronounced at equivalent milligram doses.
Pre-existing heart conditions substantially elevate risk. No 4F-MPH-specific cardiovascular safety data have been published.safety citation needed
Chronic toxicity
No data exist on chronic toxicity. Long-term stimulant use in the methylphenidate class is associated with sustained cardiovascular stress and dopamine system dysregulation.[6] Whether 4F-MPH's enhanced potency accelerates chronic damage is unknown.inferred
Psychological risks
Methylphenidate-class psychiatric adverse effects applicable to 4F-MPH include[6]:
- Anxiety, agitation, and restlessness
- Psychotic symptoms at high doses or with sleep deprivation
- Worsening of pre-existing mood disorders, including triggering of manic episodes
- Irritability and emotional dysregulation during offset
The confirmed mono-intoxication case exhibited agitation and altered mental status requiring antipsychotic medication.[7] Community reports describe post-use dysphoria, Irritability, and amotivation as common offset effects, worsening with dose and frequency.[15]
Compulsive redosing is widely reported, particularly via insufflation where rapid onset increases reinforcement.[15]
Tolerance and dependence
No published experimental data on tolerance or dependence exist for 4F-MPH. All characterization is class-inferred.
Methylphenidate maintains robust self-administration in primates comparable to cocaine, confirming substantial reinforcing efficacy for the DAT-inhibitor class.[16] Given 4F-MPH's approximately 2-fold greater DAT potency, its reinforcing efficacy is plausibly at least equivalent.
Abuse potential among monoamine reuptake inhibitors correlates primarily with DAT-to-serotonin-transporter selectivity.[5] 4F-MPH's ratio (~144:1) places it among high-liability compounds, comparable to cocaine and methylphenidate. Physical dependence, withdrawal, cross-tolerance, and tolerance development kinetics have not been studied. Community reports cite compulsive redosing as a recognized risk.[15]
Drug interactions
Tramadol
The combination carries a "lethal" severity designation. Tramadol lowers the seizure threshold and has weak serotonergic activity; combining it with a potent stimulant that independently elevates cardiovascular demand creates compounded risk.safety citation needed
MDMA
Designated "dangerous." Combined dopaminergic and noradrenergic stimulation from 4F-MPH with MDMA's serotonin release produces additive or synergistic risk of dangerously elevated heart rate, blood pressure, and body temperature.safety citation needed
Alcohol
For the parent compound methylphenidate, co-administration with alcohol produces ethylphenidate — a distinct psychoactive compound — through an enzymatic transesterification reaction, along with increased early exposure and potentiated euphoria.[17] Whether the same reaction occurs with 4F-MPH is structurally plausible but unconfirmed. Severity designation: "unknown."
Other stimulants
Combination with amphetamines, cocaine, or cathinones produces additive cardiovascular and CNS stimulant effects. The fatal US case involved polydrug use including amphetamine and methamphetamine alongside 4F-MPH.[8]
MAOIs
Combination with monoamine oxidase inhibitors is contraindicated for all stimulants due to risk of dangerously elevated blood pressure from combined catecholamine excess.inferred
Contraindications
No 4F-MPH-specific contraindication data exist. The following are inferred from the methylphenidate class[6] and apply with at least equal force given 4F-MPH's enhanced potency:
Absolute:
- Concurrent MAOI use — risk of dangerous blood pressure crisis
- Severe heart disease (structural heart disease, recent heart attack, uncontrolled irregular heart rhythm) — stimulation may trigger fatal cardiac events
- Pheochromocytoma — catecholamine potentiation with a catecholamine-secreting tumor creates extreme risk
Relative:
- High blood pressure — dose-dependent blood pressure elevation worsens uncontrolled hypertension
- Anxiety disorders — noradrenergic potentiation worsens symptoms[7]
- History of psychosis or bipolar disorder — stimulants can trigger psychotic or manic episodes
- Seizure disorders — stimulants may lower seizure threshold
- Liver impairment — if metabolism parallels methylphenidate, reduced clearance is possible
- Pregnancy and breastfeeding — no reproductive data exist; contraindicated by precaution
All contraindications are class-inferred pending substance-specific investigation.inferred
Harm Reduction[edit]
Forms & Identification
4F-MPH typically circulates as a white crystalline powder sold by online research chemical vendors. Batch-to-batch variation in diastereomeric composition — the ratio of active threo to inactive erythro forms — means that potency per milligram can vary significantly between purchases, even from the same supplier.[1] A batch that happens to contain purer threo-4F-MPH will feel substantially stronger at the same weighed dose. Reagent testing can confirm the presence of a phenidate-class compound but cannot distinguish diastereomeric ratios or differentiate 4F-MPH from related analogs.
Guidelines
- Test every batch with a reagent kit to confirm a phenidate-class compound is present
- Start with a low oral dose — potency varies between batches due to diastereomeric composition
- Weigh doses with a milligram-precision scale; do not estimate
- Set a firm cutoff time at least 8 hours before intended sleep
- Eat a full meal before dosing; appetite suppression often prevents eating during the active phase
- Stay hydrated — stimulant effects mask thirst signals
- Avoid redosing; if redosing, halve the original dose and limit to one additional administration
- Do not switch to insufflation mid-session for a "boost" — this route carries greater compulsive redosing risk
Set & Setting
4F-MPH's stimulant profile favors structured, task-oriented environments. The compound's tendency toward emotional suppression and anxious overstimulation at higher doses makes it poorly suited to social or emotionally demanding contexts. Insufflation produces a faster, sharper onset with greater compulsive redosing liability — oral administration offers a more controlled arc. Planning the session length and setting a hard cutoff time protects sleep, as residual stimulation can persist for hours after the subjective peak fades.
Aftercare & integration. The 4F-MPH comedown commonly involves dysphoria, irritability, and amotivation that can last 12–24 hours and feel disproportionate to the modest high.[15] Prioritize sleep — use blackout curtains, avoid screens, and consider magnesium or melatonin if sleep onset is difficult.
Eat a substantial meal as soon as appetite returns; extended stimulant sessions deplete energy reserves and leave the body in caloric deficit. Avoid caffeine or other stimulants in the recovery window, as they prolong cardiovascular stress and delay emotional baseline return. If dysphoria persists beyond 48 hours or use frequency is increasing, re-evaluate the pattern rather than redose.
Recovery & Support
4F-MPH's compulsive redosing profile and high DAT selectivity make escalating use patterns a recognized risk. If use has shifted from occasional productivity sessions to daily or near-daily dosing, or if attempts to stop produce significant fatigue, low mood, or cravings, professional support is warranted.
SAMHSA's National Helpline (1-800-662-4357) provides free referrals in the United States. SMART Recovery and stimulant-specific support groups offer structured frameworks for examining and changing use patterns. A healthcare provider familiar with stimulant use disorders can assess whether the pattern warrants clinical intervention.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, irregular or pounding heartbeat, seizure, loss of consciousness, severe confusion, or body temperature hot to the touch through clothing all indicate a medical emergency — not just an uncomfortable stimulant experience.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Keep the person seated or lying down in a cool, quiet environment
- 3. Do not restrain them unless they are in immediate physical danger
- 4. Remove excess clothing and apply cool water if overheating is suspected
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (4-fluoromethylphenidate / 4F-MPH), approximate dose and time taken, route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No specific reversal agent exists for stimulant intoxication. Hospital treatment is supportive — typically intravenous sedation with benzodiazepines, as documented in the confirmed mono-intoxication case.[7]
Legal Status[edit]
4F-MPH is not subject to international control under the United Nations Single Convention on Narcotic Drugs (1961) or the Convention on Psychotropic Substances (1971).[3] Regulatory responses have occurred at the national level, driven by EMCDDA Early Warning System notifications beginning in November 2015. Legal status varies substantially across jurisdictions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | The Federal Analogue Act may apply if 4F-MPH is intended for human consumption, as methylphenidate is Schedule II. Alabama has enacted state-level Schedule I control[3] |
| United Kingdom | Class B controlled drug | Scheduled 31 May 2017 under the Psychoactive Substances Act framework[9] |
| Canada | Controlled substance | Controlled since 5 May 2017[9] |
| Germany | Controlled under NpSG | Listed under the New Psychoactive Substances Act since November 2016. Reports of accidental re-legalization via regulatory omission in September 2022 could not be verifiedcitation needed |
| Australia | Likely Schedule 9 | No 4F-MPH-specific scheduling document identified; classification inferred from analogue provisions of the Poisons Standardcitation needed |
Individual EU member states have enacted varied responses beyond the EMCDDA notification; comprehensive jurisdiction-by-jurisdiction coverage is not available from published sources.
Analog act considerations
In the United States, 4F-MPH's structural relationship to methylphenidate (Schedule II) makes it a candidate for prosecution under the Federal Analogue Act (21 U.S.C. § 813), which treats substantially similar compounds as Schedule I if intended for human consumption. The "research chemical" marketing framing employed by vendors represents an attempt to circumvent this provision, though its legal efficacy varies by jurisdiction and judicial interpretation.
references
- [1] ^abcdefghijMcLaughlin G, Morris N, Kavanagh PV, Power JD, Dowling G, Twamley B, O'Brien J, Hessman G, Murphy B, Walther D, Partilla JS, Baumann MH, Brandt SD (2017) Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo and (±)-erythro diastereomers — Drug Testing and Analysis doi:10.1002/dta.2167
- [2] ^abcdLuethi D, Kaeser PJ, Brandt SD, Krähenbuhl S, Hoener MC, Liechti ME (2018) Pharmacological profile of methylphenidate-based designer drugs — Neuropharmacology doi:10.1016/j.neuropharm.2017.08.020
- [3]
- [4] ^abcdHolborn T, Schifano F, Deluca P (2023) No prescription? No problem: A qualitative study investigating self-medication with novel psychoactive substances (NPS) — The International Journal on Drug Policy doi:10.1016/j.drugpo.2023.104109
- [5] ^abcLiechti ME (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling — Swiss Medical Weekly doi:10.4414/smw.2015.14043
- [6]